HOT: first example of an organometallic osmium complex with significant anti-cancer activity

The majority of therapeutics clinically available for cancer treatment are platinum-based and work via a DNA alkylation mechanism that leads to cell apoptosis.  But a number of cancers are resistant to apoptosis and not treatable with platinum-based drugs.

In this paper Peter Sadler (University of Warwick), Steve Shnyder (University of Bradford) and teams have developed an organometallic half-sandwich osmium complex that displays significant anti-cancer activity with negligible toxicity in vivo. Osmium is also a platinum group metal but has a completely different mode of action and appears to operate via redox mechanisms – making these complexes candidates for further investigation and potentially clinical trials.

Read more about this exciting find here – the article is currently free to access:

Anti-colorectal cancer activity of an organometallic osmium arene azopyridine complex
Steve D. Shnyder, Ying Fu, Abraha Habtemariam, Sabine H. van Rijt, Patricia A. Cooper, Paul M. Loadman and Peter J. Sadler
Med. Chem. Commun., 2011, Advance Article
DOI: 10.1039/C1MD00075F

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Leave a Reply

*